-
1.发明申请公开(公告)号：US20090175883A1
公开(公告)日：2009-07-09
申请号：US12075197
申请日：2008-03-10
IPC分类号： A61K39/395 , A61P31/12
CPC分类号： C07K16/1027 , A61K9/0019 , A61K9/0043 , A61K39/39591 , A61K39/42 , A61K47/183 , A61K2039/505 , C07K2317/56 , C07K2317/565 , A61K2300/00
摘要： The present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with RSV infection utilizing the liquid formulations of the present invention.
摘要翻译： 本发明提供免疫特异性结合呼吸道合胞病毒（RSV）抗原的抗体或其片段的液体制剂，该制剂表现出稳定性，低至不可检测的聚集水平，以及抗体的生物活性几乎至不损失，或 抗体片段，即使在长时间的储存期间。 特别地，本发明提供免疫特异性结合RSV抗原的抗体或其片段的液体制剂，该制剂基本上不含表面活性剂，无机盐和/或其它常见的赋形剂。 此外，本发明提供使用本发明的液体制剂预防，治疗或改善与RSV感染相关的一种或多种症状的方法。
-
2.发明申请Stabilized High Concentration Anti-Integrin alphavbeta3 Antibody Formulations 审中-公开稳定的高浓度抗整合素αphbb3抗体制剂公开(公告)号：US20090053238A1
公开(公告)日：2009-02-26
申请号：US11462277
申请日：2006-08-03
申请人： Christian B. ALLAN
发明人： Christian B. ALLAN
IPC分类号： A61K39/395
CPC分类号： A61K31/198 , A61K2039/505 , C07K16/2848 , C07K2317/90 , A61K2300/00
摘要： The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to integrin αVβ3, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to integrin αVβ3, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating an inflammatory disorder, an autoimmune disorder, a disorder associated with aberrant expression and/or activity of integrin αVβ3, a disorder associated with abnormal bone metabolism, a disorder associated with aberrant angiogenesis or cancer utilizing the liquid formulations of the present invention.
摘要翻译： 本发明提供免疫特异性结合整联蛋白αVβ3的抗体或抗体片段的液体制剂，该制剂表现出稳定性，低至不可检测的聚集水平，以及甚至在长时间内抗体或抗体片段的生物活性也几乎不损失 储存期 特别地，本发明提供免疫特异性结合整联蛋白αVβ3的抗体或其片段的液体制剂，该制剂基本上不含表面活性剂，无机盐和/或其它常见赋形剂。 此外，本发明提供了预防，治疗或改善炎性病症，自身免疫病症，与整合素αVβ3异常表达和/或活性相关的病症，与异常骨代谢相关的疾病，与异常血管生成或癌症相关的病症的方法 利用本发明的液体制剂。
-
公开(公告)号：US20080299134A1
公开(公告)日：2008-12-04
申请号：US12049566
申请日：2008-03-17
申请人： Jennifer Lynne Reed , William Dall'Acqua , Jacques Van Snick , Jean-Christophe Renauld , Francoise Cormont , Catherine Uyttenhove
发明人： Jennifer Lynne Reed , William Dall'Acqua , Jacques Van Snick , Jean-Christophe Renauld , Francoise Cormont , Catherine Uyttenhove
IPC分类号： A61K39/395 , C07K16/18 , A61P43/00
CPC分类号： C07K16/244 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/76
摘要： The application describes neutralizing chimeric and humanized anti-human IL-9 antibodies, and the use thereof to identify neutralizing epitopes on human IL-9 and as medicaments to prevent and treat asthma, bronchial hyperresponsiveness, atopic allergy, and other related disorders. Particularly disclosed are recombinant antibodies derived from three murine anti-human IL-9 antibodies identified infra as MH9A3, MH9D1, and MH9L1.
摘要翻译： 该应用描述了中和嵌合和人源化抗人IL-9抗体，以及其用于鉴定人IL-9上的中和表位以及用作预防和治疗哮喘，支气管高反应性，特应性变态反应和其它相关疾病的药物。 特别公开的是衍生自以下鉴定的三种鼠抗人IL-9抗体作为MH9A3，MH9D1和MH9L1的重组抗体。
-
公开(公告)号：US20080286270A1
公开(公告)日：2008-11-20
申请号：US11906543
申请日：2007-10-01
IPC分类号： A61K39/395 , A61P11/00
CPC分类号： C07K16/1027 , A61K9/0019 , A61K9/0043 , A61K39/39591 , A61K39/42 , A61K47/183 , A61K47/22 , A61K47/26 , A61K2039/505 , A61K2039/54 , C07K16/00 , C07K2317/24 , C07K2317/565 , C07K2317/94
摘要： The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
摘要翻译： 本发明提供了免疫特异性结合呼吸道合胞病毒（RSV）抗原的SYNAGIS或其抗原结合片段的液体制剂，该制剂表现出稳定性，低至不可检测的聚集水平，以及很少甚至没有损失 SYNAGIS或其抗原结合片段的生物活性，甚至在长时间的储存期间。 特别地，本发明提供了SYNAGIS或其抗原结合片段的液体制剂，其免疫特异性结合RSV抗原，该制剂基本上不含表面活性剂，无机盐和/或其它常见赋形剂。 此外，本发明提供使用本发明的液体制剂预防，治疗或改善与RSV感染相关的症状的方法。
-
5.发明授权公开(公告)号：US07425618B2
公开(公告)日：2008-09-16
申请号：US10461863
申请日：2003-06-13
IPC分类号： C12P21/08
CPC分类号： C07K16/1027 , A61K9/0019 , A61K9/0043 , A61K39/39591 , A61K39/42 , A61K47/183 , A61K2039/505 , C07K2317/56 , C07K2317/565 , A61K2300/00
摘要： The present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with RSV infection utilizing the liquid formulations of the present invention.
摘要翻译： 本发明提供免疫特异性结合呼吸道合胞病毒（RSV）抗原的抗体或其片段的液体制剂，该制剂表现出稳定性，低至不可检测的聚集水平，以及抗体的生物活性几乎至不损失，或 抗体片段，即使在长时间的储存期间。 特别地，本发明提供免疫特异性结合RSV抗原的抗体或其片段的液体制剂，该制剂基本上不含表面活性剂，无机盐和/或其它常见的赋形剂。 此外，本发明提供使用本发明的液体制剂预防，治疗或改善与RSV感染相关的一种或多种症状的方法。
-
6.发明申请Recombinant Parainfluenza Virus Expression Systems And Vaccines Comprising Heterologous Antigens Derived From Respiratory Syncytial Virus 审中-公开重组副流感病毒表达系统和疫苗，其包含来自呼吸道合胞病毒的异源抗原公开(公告)号：US20080096263A1
公开(公告)日：2008-04-24
申请号：US11762814
申请日：2007-06-14
申请人： Aurelia Haller , Kathleen Coelingh
发明人： Aurelia Haller , Kathleen Coelingh
IPC分类号： C12N7/00
CPC分类号： C12Q1/701 , A61K39/12 , A61K39/155 , A61K2039/5254 , A61K2039/5256 , A61K2039/545 , A61K2039/552 , A61K2039/58 , A61K2039/70 , A61K2123/00 , C07K14/005 , C07K16/1027 , C12N7/00 , C12N15/86 , C12N2710/22034 , C12N2760/18321 , C12N2760/18322 , C12N2760/18334 , C12N2760/18343 , C12N2760/18522 , C12N2760/18534 , C12N2760/18621 , C12N2760/18622 , C12N2760/18634 , C12N2760/18643 , C12N2840/203 , C12Q2600/158 , G01N33/5008 , G01N33/5011 , G01N33/502 , G01N33/5088 , G01N33/56983 , G01N2333/08 , Y02A90/26
摘要： The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. In particular, the heterologous gene products include gene product of another species of PIV or from another negative strand RNA virus, including but not limited to, influenza virus, respiratory syncytial virus, human metapneumovirus and avian pneumovirus. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.
摘要翻译： 本发明涉及可用于在合适的宿主细胞系统中表达异源基因产物的重组牛副流感病毒（bPIV）cDNA或RNA，和/或挽救表达，包装和/或呈递异源的负链RNA重组病毒 基因产物。 特别地，异源基因产物包括另一种PIV或另一种负链RNA病毒的基因产物，包括但不限于流感病毒，呼吸道合胞病毒，人偏肺病毒和禽肺病毒。 嵌合病毒和表达产物可有利地用于疫苗制剂中，包括针对各种病原体和抗原的疫苗。
-
7.发明授权Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment 有权给予/给予抗RSV抗体进行预防和治疗的方法公开(公告)号：US07229619B1
公开(公告)日：2007-06-12
申请号：US09724531
申请日：2000-11-28
申请人： James F. Young , Scott Koenig , Leslie S. Johnson , William D. Huse , Jeffrey D. Watkins , Herren Wu
发明人： James F. Young , Scott Koenig , Leslie S. Johnson , William D. Huse , Jeffrey D. Watkins , Herren Wu
IPC分类号： A61K39/42
CPC分类号： C07K16/1027 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565
摘要： The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis a RSV infection.
摘要翻译： 本发明包括免疫特异性结合一种或多种RSV抗原的新型抗体及其片段，以及包含所述抗体和抗体片段的组合物。 本发明包括预防人类呼吸道合胞病毒（RSV）感染的方法，包括向所述人施用预防有效量的一种或多种免疫特异性结合一种或多种RSV抗原的抗体或其片段，其中一定的血清滴度为 所述抗体或抗体片段在所述人受试者中实现。 本发明还包括用于治疗或改善与人类RSV感染有关的症状的方法，包括向所述人施用治疗有效量的一种或多种免疫特异性结合一种或多种RSV抗原的抗体或其片段，其中一定 所述抗体或抗体片段的血清滴度在所述人受试者中实现。 本发明还包括包含免疫特异性结合RSV抗原的抗体或其片段的组合物，以及使用所述组合物检测或诊断RSV感染的方法。
-
公开(公告)号：US07229618B2
公开(公告)日：2007-06-12
申请号：US11207142
申请日：2005-08-17
申请人： Leslie S. Johnson , Bradford Braden
发明人： Leslie S. Johnson , Bradford Braden
IPC分类号： A61K39/00 , A61K39/395 , C12P21/08
CPC分类号： C07K16/1027 , C07K2299/00 , C07K2317/24 , C07K2317/55
摘要： The present invention provides crystalline forms and three-dimensional atomic structure coordinates of Synagis Fab. The present invention further provides methods of using such three-dimensional atomic structure coordinates for designing and identifying Synagis binding agents. The present invention also provides machine readable media embedded with the three-dimensional atomic structure coordinates of Synagis Fab and methods of using them.
摘要翻译： 本发明提供了Synagis Fab的结晶形式和三维原子结构坐标。 本发明还提供了使用这种三维原子结构坐标来设计和鉴定Synagis粘合剂的方法。 本发明还提供嵌入了Synagis Fab的三维原子结构坐标的机器可读介质及其使用方法。
-
公开(公告)号：US20070122403A1
公开(公告)日：2007-05-31
申请号：US11649455
申请日：2007-01-03
CPC分类号： C07K16/283 , A61K38/00 , A61K39/00 , A61K47/48507 , A61K47/6835 , A61K49/0002 , A61K49/0004 , A61K2039/505 , C07K2/00 , C07K14/70503 , C07K16/00 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/53 , C07K2317/94 , C07K2319/00 , C07K2319/30 , Y10S435/81
摘要： The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
摘要翻译： 本发明提供了由于存在IgG恒定结构域或其结合FcRn的部分而具有增加的体内半衰期的IgG，非IgG免疫球蛋白，蛋白质和非蛋白质试剂的分子，其具有一个 或更多的氨基酸修饰，其增加FcRn的恒定结构域或片段的亲和力。 具有增加的半衰期的这种蛋白质和分子具有在这种分子的治疗，预防或诊断使用中需要更少量和/或更低频率给药的优点。
-
公开(公告)号：US20070092523A1
公开(公告)日：2007-04-26
申请号：US11562676
申请日：2006-11-22
申请人： Leslie Johnson
发明人： Leslie Johnson
IPC分类号： A61K39/42 , A61K31/7056 , A61K31/13
CPC分类号： C07K16/248 , A61K39/42 , A61K2039/505 , C07K16/1027 , A61K2300/00
摘要： Therapeutically effective anti-microbial compositions, useful especially against respiratory diseases caused or mediated by viruses, bacteria, and other respiratory parasites are disclosed, wherein said compositions comprise at least one neutralizing antibody, including high affinity antibodies, and an additional anti-infectious agent, such as an antiviral agent, for example, ribavirin, amantadine, rimantadine, or a neuraminidase-inhibitor. or antibacterial agents, including other antibodies. Also disclosed are methods of using such compositions to treat and/or prevent respiratory and related diseases.
摘要翻译： 公开了治疗上有效的抗微生物组合物，特别是针对由病毒，细菌和其他呼吸寄生虫引起或介导的呼吸系统疾病，其中所述组合物包含至少一种中和抗体，包括高亲和力抗体和另外的抗感染剂， 例如抗病毒剂，例如利巴韦林，金刚烷胺，金刚乙胺或神经氨酸酶抑制剂。 或抗菌剂，包括其他抗体。 还公开了使用这种组合物治疗和/或预防呼吸系统和相关疾病的方法。
-
-
-
-
-
-
-
-
-
搜索结果
100 条记录 (耗时 0.069 秒)
